Pharmacodynamics-Mediated drug disposition (PDMDD) and precursor pool lifespan model for single dose of romiplostim in healthy subjects

AAPS Journal

Volumn 12, Issue 4, 2010, Pages 729-740

  Wang, Yow Ming C ^a   Krzyzanski, Wojciech ^b   Doshi, Sameer ^a   Xiao, Jim J ^a   Pérez Ruixo, Juan Jose ^a   Chow, Andrew T ^a  

^a AMGEN INC   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

Author keywords

Lifespan model; Pharmacodynamics mediated drug disposition (PDMDD); Platelets; Romiplostim; Thrombopoiesis receptor agonist

Indexed keywords

PLACEBO; ROMIPLOSTIM;

ADULT; ARTICLE; CELL SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXPOSURE; ENDOCYTOSIS; FEMALE; HUMAN; HUMAN EXPERIMENT; INTERNALIZATION; MALE; NORMAL HUMAN; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SIMULATION; SINGLE DRUG DOSE; THROMBOCYTE COUNT;

ADOLESCENT; ADULT; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; RECEPTORS, FC; RECEPTORS, THROMBOPOIETIN; RECOMBINANT FUSION PROTEINS; REFERENCE VALUES; THROMBOPOIETIN; YOUNG ADULT;

EID: 78649648378     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-010-9234-9     Document Type: Article

References (30)

1. AE Geddis HM Linden K Kaushansky 2002 Thrombopoietin: a pan-hematopoietic cytokine Cytokine Growth Factor Rev 13 61 73 1:CAS:528:DC%2BD3MXpt1ahurs%3D 10.1016/S1359-6101(01)00030-2 11750880 (Pubitemid 34436962)
2. JE Cardier J Dempsey 1998 Thrombopoietin and its receptor, c-mpl, are constitutively expressed by mouse liver endothelial cells: evidence of thrombopoietin as a growth factor for liver endothelial cells Blood 91 923 9 1:CAS:528:DyaK1cXovFSksQ%3D%3D 9446653
3. R Sungaran B Markovic BH Chong 1997 Localization and regulation of thrombopoietin mRNa expression in human kidney, liver, bone marrow, and spleen using in situ hybridization Blood 89 101 7 1:CAS:528:DyaK2sXhsFejsg%3D%3D 8978282
4. DJ Kuter RD Rosenberg 1995 The reciprocal relationship of thrombopoietin (c-Mpl ligand) to changes in the platelet mass during busulfan-induced thrombocytopenia in the rabbit Blood 85 2720 30 1:CAS:528:DyaK2MXls1Sru70%3D 7742532
5. J Li C Yang Y Xia A Bertino J Glaspy M Roberts, et al. 2001 Thrombocytopenia caused by the development of antibodies to thrombopoietin Blood 98 3241 8 1:CAS:528:DC%2BD3MXovVSgs70%3D 10.1182/blood.V98.12.3241 11719360
6. RL Basser E O'Flaherty M Green M Edmonds J Nichol DM Menchaca, et al. 2002 Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor Blood 99 2599 602 1:CAS:528:DC%2BD38XisFGhtr8%3D 10.1182/blood.V99.7.2599 11895799 (Pubitemid 34525451)
7. B Wang JL Nichol JT Sullivan 2004 Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand Clin Pharmacol Ther 76 628 38 1:CAS:528:DC%2BD2cXhtVKlt7vJ 10.1016/j.clpt.2004.08.010 15592334 (Pubitemid 39601552)
8. J Li Y Xia DJ Kuter 1999 Interaction of thrombopoietin with the platelet c-mpl receptor in plasma: binding, internalization, stability and pharmacokinetics Br J Haematol 106 345 56 1:CAS:528:DyaK1MXlvVOhsrc%3D 10.1046/j.1365-2141.1999.01571.x 10460590 (Pubitemid 29450656)
9. PJ Fielder P Hass M Nagel E Stefanich R Widmer GL Bennett, et al. 1997 Human platelets as a model for the binding and degradation of thrombopoietin Blood 89 2782 8 1:CAS:528:DyaK2sXisFCis70%3D 9108396
10. VC Broudy NL Lin DF Sabath T Papayannopoulou K Kaushansky 1997 Human platelets display high-affinity receptors for thrombopoietin Blood 89 1896 904 1:CAS:528:DyaK2sXhvVaku7w%3D 9058709
11. DE Mager WJ Jusko 2001 General pharmacokinetic model for drugs exhibiting target-mediated drug disposition J Pharmacokinet Pharmacodyn 28 507 32 1:CAS:528:DC%2BD38XjsFSrtro%3D 10.1023/A:1014414520282 11999290 (Pubitemid 34289541)
12. DE Mager W Krzyzanski 2005 Quasi-equilibrium pharmacokinetic model for drugs exhibiting target-mediated drug disposition Pharm Res 22 1589 96 1:CAS:528:DC%2BD2MXhtVent7vO 10.1007/s11095-005-6650-0 16180117 (Pubitemid 41355898)
13. LA Harker LK Roskos UM Marzec RA Carter JK Cherry B Sundell, et al. 2000 Effects of megakaryocyte growth and development factor on platelet production, platelet life span, and platelet function in healthy human volunteers Blood 95 2514 22 1:CAS:528:DC%2BD3cXisVaisbg%3D 10753829
14. LK Roskos P Lum P Lockbaum G Schwab BB Yang 2006 Pharmacokinetic/ pharmacodynamic modeling of pegfilgrastim in healthy subjects J Clin Pharmacol 46 747 57 1:CAS:528:DC%2BD28XntlWgsbo%3D 10.1177/0091270006288731 16809800 (Pubitemid 43882798)
15. JJ Perez-Ruixo W Krzyzanski J Hing 2008 Pharmacodynamic analysis of recombinant human erythropoietin effect on reticulocyte production rate and age distribution in healthy subjects Clin Pharmacokinet 47 399 415 1:CAS:528:DC%2BD1cXos1ehsrs%3D 10.2165/00003088-200847060-00004 18479174 (Pubitemid 351685389)
16. Brown AS, Erusalamsky JD, Martin JF. Megakaryocytopoiesis: the megakaryocyte/platelet haemostatic axis. In: Franz von Bruchhausen UW, editor. Platelets and their factors. Berlin: Springer; 1997. p. 3-26.
17. F Jin W Krzyzanski 2004 Pharmacokinetic model of target-mediated disposition of thrombopoietin Aaps J 6 86 93 18465261
18. T Sato A Fuse H Niimi PJ Fielder H Avraham 1998 Binding and regulation of thrombopoietin to human megakaryocytes Br J Haematol 100 704 11 1:CAS:528:DyaK1cXitlylur8%3D 10.1046/j.1365-2141.1998.00622.x 9531337 (Pubitemid 28126103)
19. DJ Kuter CG Begley 2002 Recombinant human thrombopoietin: basic biology and evaluation of clinical studies Blood 100 3457 69 1:CAS:528: DC%2BD38XoslKmtL0%3D 10.1182/blood.V100.10.3457 12411315 (Pubitemid 35303910)
20. MN Samtani JJ Perez-Ruixo KH Brown D Cerneus CJ Molloy 2009 Pharmacokinetic and pharmacodynamic modeling of pegylated thrombopoietin mimetic peptide (PEG-TPOm) after single intravenous dose administration in healthy subjects J Clin Pharmacol 49 336 50 1:CAS:528:DC%2BD1MXjslamtbY%3D 10.1177/0091270008329559 19246731
21. Jackson C, Arnold JT, Pestina TI, Stenberg PE. Megakaryocyte biology. In: Kuter DJ, Hunt P, Sheridan W, Zucker-Franklin D, editors. Thromobopoiesis and thrombopoietins; molecular, cellular, preclinical, and clinical biology. Totowa: Humana; 1997. p. 3-40.
22. W Krzyzanski R Ramakrishnan WJ Jusko 1999 Basic pharmacodynamic models for agents that alter production of natural cells J Pharmacokinet Biopharm 27 467 89 1:CAS:528:DC%2BD3cXlvV2jsbk%3D 10948694
23. RP Stephenson 1956 A modification of receptor theory Br J Pharmacol Chemother 11 379 93 1:CAS:528:DyaG2sXltlGhtw%3D%3D 13383117
24. N Holford 1984 Drug concentration, binding, and effect in vivo Pharm Res 1 102 5 10.1023/A:1016367701698
25. H Derendorf B Meibohm 1999 Modeling of pharmacokinetic/pharmacodynamic (PK/PD) relationships: concepts and perspectives Pharm Res 16 176 85 1:CAS:528:DyaK1MXhvFylsb4%3D 10.1023/A:1011907920641 10100300 (Pubitemid 29135119)
26. DE Mager E Wyska WJ Jusko 2003 Diversity of mechanism-based pharmacodynamic models Drug Metab Dispos 31 510 8 1:CAS:528:DC%2BD3sXjt1Ggtrg%3D 10.1124/dmd.31.5.510 12695336 (Pubitemid 36444157)
27. L Zhang SL Beal LB Sheiner 2003 Simultaneous vs. sequential analysis for population PK/PD data I: best-case performance J Pharmacokinet Pharmacodyn 30 387 404 10.1023/B:JOPA.0000012998.04442.1f 15000421 (Pubitemid 38221931)
28. G Levy 1994 Pharmacologic target-mediated drug disposition Clin Pharmacol Ther 56 248 52 1:STN:280:DyaK2M%2FgvVGqsw%3D%3D 10.1038/clpt.1994.134 7924119
29. EI Ette PJ Williams YH Kim JR Lane MJ Liu EV Capparelli 2003 Model appropriateness and population pharmacokinetic modeling J Clin Pharmacol 43 610 23 1:CAS:528:DC%2BD3sXkslGhsbw%3D 12817524
30. AK Abraham W Krzyzanski DE Mager 2007 Partial derivative-based sensitivity analysis of models describing target-mediated drug disposition Aaps J 9 E181 9 10.1208/aapsj0902020 17614360